An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ, Hutchinson KE, Rexer BN, Estrada MV, Gonzalez Ericsson PI, Sanders ME, Dugger TC, Formisano L, Guerrero-Zotano A, Red-Brewer M, Young CD, Lantto J, Pedersen MW, Kragh M, Horak ID, Arteaga CL.
Schwarz LJ, et al. Among authors: dugger tc.
J Natl Cancer Inst. 2017 Nov 1;109(11):djx065. doi: 10.1093/jnci/djx065.
J Natl Cancer Inst. 2017.
PMID: 29059433
Free PMC article.